ERIC THOMAS SCHMIDT - 22 Mar 2023 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role
Chief Financial Officer
Signature
/s/Veer Bhavnagri, Attorney-in-Fact
Issuer symbol
ALLO
Transactions as of
22 Mar 2023
Net transactions value
$0
Form type
4
Filing time
24 Mar 2023, 20:17:56 UTC
Previous filing
16 Mar 2023
Next filing
30 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLO Common Stock Award $0 +558,094 +183% $0.000000 862,439 22 Mar 2023 Direct F1
holding ALLO Common Stock 1,152,595 22 Mar 2023 See footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALLO Stock Option (Right to Buy) Award $0 +432,738 $0.000000 432,738 22 Mar 2023 Common Stock 432,738 $5.04 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 429,303 of performance RSUs which shall vest as follows: (1) 50% shall vest if the 30-day weighted average stock price is equal to or greater than $18 and (2) 50% shall vest upon the first regulatory approval of a product candidate. Notwithstanding the foregoing (1) any portion that vests upon the stock price threshold shall no longer vest and be terminated after three years from the grant date if such threshold has not been met in such three-year period, and (2) any portion that vests upon product candidate approval shall no longer vest and be terminated after five years from the grant date if such approval has not occurred in such five-year period.
F2 The securities are held in the name of the Eric Schmidt 2017 Family Irrevocable Trust
F3 25% of the shares subject to the stock option shall vest on March 13, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.